Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.8 EUR | -0.44% |
|
+1.86% | +43.92% |
12:42pm | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
09:22am | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.15 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+43.92% | 638B | - | ||
+56.03% | 819B | C+ | ||
-6.93% | 351B | C+ | ||
+17.29% | 329B | B- | ||
+9.60% | 298B | C+ | ||
+16.57% | 242B | B+ | ||
+2.04% | 225B | A+ | ||
+13.31% | 217B | B- | ||
+8.18% | 168B | C+ | ||
-2.80% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVO B Stock
- NOV Stock
- Ratings Novo Nordisk A/S